Project Grant R01CA304719
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $532K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award for $546,133 was provided by the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The grant supports a multi-year research project to investigate the nuclear and non-nuclear functions of the NKX3.1 gene in suppressing prostate cancer progression, particularly as it relates to aging and mitochondrial...
- The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the Weill Medical College of Cornell University to investigate the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The $683,979 award, effective June 1, 2025 through April 30, 2030, will fund a multi-institutional collaborative effort to define the propensity of prostate cancers harboring SPOP mutations to progress to specific subtypes...
- This federal Project Grant award of $714,317.00 from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York. The goal is to investigate the mechanisms linking epithelial-mesenchymal transition (EMT), anoikis resistance, and the tumor microenvironment in the progression of metastatic castration-resistant prostate cancer. Key research objectives include determining how...
- This $564,543 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393). The grant supports research at the Weill Medical College of Cornell University to investigate how the androgen receptor (AR) governs normal, growth-suppressive gene expression in prostate cells, and how this program becomes hijacked to drive oncogenic transcription in prostate cancer. The research aims to determine if the normal,...
- This Project Grant award, totaling $354,658, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Johns Hopkins University. The objective is to perform a systematic analysis of P27 alterations in both primary and metastatic prostate cancer, with the ultimate aim of understanding how subclonal P27 loss mediates worse prostate cancer outcomes, particularly in African American males who experience higher mortality rates from the disease. This research...
- This federal Project Grant award of $545,078, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is supporting research at The Johns Hopkins University to investigate the use of radiopharmaceutical therapy in combination with inhibition of glutamine metabolism as a novel therapeutic strategy for prostate cancer and renal cell carcinoma. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,972 to the University of California, Los Angeles (UCLA) to conduct research on overcoming radiopharmaceutical therapy resistance in prostate cancer. The key focus is to investigate how the enzyme ENPP1 impacts the effectiveness of PSMA-targeting radiopharmaceutical therapy (RPT) by regulating immune signaling pathways in the tumor microenvironment. The research aims to define...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The project aims to identify key transcriptional regulators that repress androgen receptor signaling and promote alternate differentiation programs in prostate cancer, with the goal of preventing lineage plasticity and disease progression. By...
- The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...